Terms: = Pancreatic cancer AND CCND1, BCL1, 595, ENSG00000110092, PRAD1, U21B31, D11S287E AND Treatment
32 results:
1. Glucagon-Like Peptide-1 Receptor Agonists and pancreatic cancer Risk in Patients With Type 2 Diabetes.
Dankner R; Murad H; Agay N; Olmer L; Freedman LS
JAMA Netw Open; 2024 Jan; 7(1):e2350408. PubMed ID: 38175642
[TBL] [Abstract] [Full Text] [Related]
2. Long noncoding RNA CASC9 promotes pancreatic cancer progression by acting as a ceRNA of miR-497-5p to upregulate expression of ccnd1.
Zhou J; Song G; Su M; Zhang H; Yang T; Song Z
Environ Toxicol; 2023 Jun; 38(6):1251-1264. PubMed ID: 36947456
[TBL] [Abstract] [Full Text] [Related]
3. Splenectomy and azygoportal disconnection decreases the risk of hepatocellular carcinoma for cirrhosis patients with portal hypertension bleeding: a 10-year retrospective follow-up study based on the inverse probability of treatment weighting method.
Gao TM; Zhou J; Xiang XX; Jin SJ; Qian JJ; Zhang C; Zhou BH; Tang H; Bai DS; Jiang GQ
J Gastroenterol; 2023 May; 58(5):503-512. PubMed ID: 36943530
[TBL] [Abstract] [Full Text] [Related]
4. Silencing of KNTC1 inhibits hepatocellular carcinoma cells progression via suppressing PI3K/Akt pathway.
Tong H; Liu X; Peng C; Shen B; Zhu Z
Cell Signal; 2023 Jan; 101():110498. PubMed ID: 36273753
[TBL] [Abstract] [Full Text] [Related]
5. Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy.
Shen J; Qi W; Dai J; Leng S; Jiang K; Zhang Y; Ran S; Li C; Wen T
Chin Med J (Engl); 2021 Dec; 135(3):301-308. PubMed ID: 34958539
[TBL] [Abstract] [Full Text] [Related]
6. FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways.
Wu SQ; Huang SH; Lin QW; Tang YX; Huang L; Xu YG; Wang SP
Pharmacol Res; 2022 Jan; 175():106040. PubMed ID: 34954029
[TBL] [Abstract] [Full Text] [Related]
7. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract] [Full Text] [Related]
8. Pharmacoeconomic Evaluation of Erlotinib for the treatment of pancreatic cancer.
Bao K; Li X; He X; Jian L
Clin Ther; 2021 Jun; 43(6):1107-1115. PubMed ID: 34059328
[TBL] [Abstract] [Full Text] [Related]
9. Extra-appendicular neuroendocrine tumors: A report from the TREP project (2000-2020).
Virgone C; Ferrari A; Chiaravalli S; De Pasquale MD; Inserra A; D'Angelo P; Ogunleye MF; Crocoli A; Vallero S; Cesaro S; Alaggio R; Bisogno G; Dall'Igna P
Pediatr Blood Cancer; 2021 Apr; 68(4):e28880. PubMed ID: 33522705
[TBL] [Abstract] [Full Text] [Related]
10. Deep Targeted Sequencing and Its Potential Implication for cancer Therapy in Chinese Patients with Gastric Adenocarcinoma.
Yu P; Wang Y; Yu Y; Wang A; Huang L; Zhang Y; Liu W; Wu H; Yao M; Du YA; Cheng X
Oncologist; 2021 May; 26(5):e756-e768. PubMed ID: 33511732
[TBL] [Abstract] [Full Text] [Related]
11. Juglone can inhibit angiogenesis and metastasis in pancreatic cancer cells by targeting Wnt/β-catenin signaling.
Gokturk F; Erkoc-Kaya D; Arikoglu H
Bratisl Lek Listy; 2021; 122(2):132-137. PubMed ID: 33502882
[TBL] [Abstract] [Full Text] [Related]
12. LRH-1 (liver receptor homolog-1) derived affinity peptide ligand to inhibit interactions between β-catenin and LRH-1 in pancreatic cancer cells: from computational design to experimental validation.
Pouraghajan K; Mahdiuni H; Ghobadi S; Khodarahmi R
J Biomol Struct Dyn; 2022 Apr; 40(7):3082-3097. PubMed ID: 33183172
[TBL] [Abstract] [Full Text] [Related]
13. Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer.
Uehara M; Domoto T; Takenaka S; Bolidong D; Takeuchi O; Miyashita T; Minamoto T
Cancer Sci; 2020 Dec; 111(12):4405-4416. PubMed ID: 32986894
[TBL] [Abstract] [Full Text] [Related]
14. MiR-93 suppresses tumorigenesis and enhances chemosensitivity of breast cancer via dual targeting E2F1 and ccnd1.
Bao C; Chen J; Chen D; Lu Y; Lou W; Ding B; Xu L; Fan W
Cell Death Dis; 2020 Aug; 11(8):618. PubMed ID: 32796817
[TBL] [Abstract] [Full Text] [Related]
15. Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for treatment of Metastatic cancer.
Kandil SB; Jones SR; Smith S; Hiscox SE; Westwell AD
Molecules; 2020 Jul; 25(15):. PubMed ID: 32751931
[TBL] [Abstract] [Full Text] [Related]
16. Integrated Analyses Identify Immune-Related Signature Associated with Qingyihuaji Formula for treatment of pancreatic Ductal Adenocarcinoma Using Network Pharmacology and Weighted Gene Co-Expression Network.
Qian X; Chen Z; Chen SS; Liu LM; Zhang AQ
J Immunol Res; 2020; 2020():7503605. PubMed ID: 32537471
[TBL] [Abstract] [Full Text] [Related]
17. Long noncoding RNA SOX2OT promotes the proliferation of pancreatic cancer by binding to FUS.
Chen L; Zhang J; Chen Q; Ge W; Meng L; Huang X; Shen P; Yuan H; Shi G; Miao Y; Jiang K
Int J Cancer; 2020 Jul; 147(1):175-188. PubMed ID: 31837005
[TBL] [Abstract] [Full Text] [Related]
18. Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy.
Xu L; Cheng Z; Cui C; Wu X; Yu H; Guo J; Kong Y
J Transl Med; 2019 Jul; 17(1):245. PubMed ID: 31358010
[TBL] [Abstract] [Full Text] [Related]
19. HiFreSP: A novel high-frequency sub-pathway mining approach to identify robust prognostic gene signatures.
Li M; Zhao J; Li X; Chen Y; Feng C; Qian F; Liu Y; Zhang J; He J; Ai B; Ning Z; Liu W; Bai X; Han X; Wu Z; Xu X; Tang Z; Pan Q; Xu L; Li C; Wang Q; Li E
Brief Bioinform; 2020 Jul; 21(4):1411-1424. PubMed ID: 31350847
[TBL] [Abstract] [Full Text] [Related]
20. Long non‑coding RNA plasmacytoma variant translocation 1 gene promotes the development of cervical cancer via the NF‑κB pathway.
Wang C; Zou H; Yang H; Wang L; Chu H; Jiao J; Wang Y; Chen A
Mol Med Rep; 2019 Sep; 20(3):2433-2440. PubMed ID: 31322217
[TBL] [Abstract] [Full Text] [Related]
[Next]
